RARE: Gene Therapy Milestones Will Support 2027 Profitability And Renew Pipeline Confidence

Ultragenyx Pharmaceutical's updated analyst price target has shifted modestly as analysts balance a slightly lower fair value estimate of about $52.05 per share with revised assumptions for higher revenue, stronger profit margins, and a lower future P/E, supported by recent research that highlights differing views on the potential of GTX-102 and the broader pipeline.

Analyst Commentary

Recent Street research on Ultragenyx shows a wide range of views, with some analysts lifting price targets on the back of GTX-102 and others trimming targets or downgrading the stock as they reassess key programs and pipeline risk.

Bullish Takeaways

Bullish analysts see GTX-102 as a key driver for potential value creation, highlighting that the Phase 3 design in Angelman syndrome uses two non hierarchical primary endpoints. They view this as offering more than one potential route to statistical success and, in turn, to supporting the investment case.
Some recent target hikes, including a move into the mid US$90s, indicate that a portion of the Street is prepared to assign material value to GTX-102 and the broader pipeline, at least relative to prior target levels.
JPMorgan, even while trimming its target, maintains an Overweight stance and explicitly flags that positive clinical data for GTX-102 could be important for the stock to gain more fundamental credit. This keeps upside scenarios on the table in their framework.
Bullish analysts also point to the existing commercial business, with JPMorgan estimating that this segment alone could justify a share value in the high teens to low US$20s. They see pipeline optionality on top of that base.

Bearish Takeaways

Several research shops have made small downward adjustments to their price targets, indicating caution around execution risk and the timing or reliability of key clinical milestones.
JPMorgan lowered its target from US$120 to US$74 and explicitly states that, at current share levels, the market is assigning no value to GTX-102 and essentially minimal value to the broader pipeline. This underscores concerns that investors may be discounting future programs heavily.
Following a setback late last year, JPMorgan reduced its peak sales expectations and probability of success for setrusumab, which feeds through to a more conservative assessment of the company’s long term revenue opportunity.
Bearish analysts view the gap between the theoretical value of the commercial business and the implied value of the pipeline as a sign that investors remain cautious about clinical risk, regulatory outcomes, and the company’s ability to translate R&D into durable earnings power.

What's in the News

Ultragenyx reaffirmed total revenue guidance of US$730 million to US$760 million for 2026 and indicated it remains on a path to profitability in 2027. Source: company guidance.
The FDA accepted for review Ultragenyx's resubmitted BLA for UX111, an AAV9 gene therapy for Sanfilippo syndrome Type A, with a PDUFA action date set for September 19, 2026. Source: company announcement.
Long term UX111 clinical data, with up to 8 years of follow up, were included in the BLA and presented at WORLDSymposium 2026. The FDA previously acknowledged robust neurodevelopmental outcome data and supportive biomarker evidence. Source: company announcement.
The FDA cleared the IND for UX016, a small molecule prodrug of sialic acid for GNE myopathy. An externally funded Phase 1/2 study in about 24 adults is expected to begin in the second half of 2026. Source: company announcement.
Ultragenyx reported positive Phase 3 Enh3ance data for DTX301 in OTC deficiency, showing a statistically significant 18% reduction in 24 hour plasma ammonia at Week 36 versus placebo and an acceptable safety profile. A second primary endpoint readout is expected in the first half of 2027. Source: company announcement.

Valuation Changes

Fair Value: $52.05 per share, slightly lower than the prior $52.45 estimate.
Discount Rate: 7.96%, modestly lower than the previous 8.16%, reflecting updated risk assumptions in the model.
Revenue Growth: 25.35% now used in the forecast, above the earlier 24.02% assumption.
Net Profit Margin: 8.64% margin assumption, up from 5.38% previously, indicating a higher modeled level of profitability.
Future P/E: 59.7x, down meaningfully from 98.0x, implying a lower valuation multiple applied to future earnings in the updated work.

11 views

Key Takeaways

Expansion of the rare disease market and favorable regulatory environment are driving strong revenue growth and pricing power for Ultragenyx's therapies.
Advancing late-stage pipeline, successful product launches, and gene therapy innovation position the company for diversified growth and improved profitability.
Ongoing losses, regulatory setbacks, pricing pressures, industry competition, and reliance on key launches and vouchers threaten revenue growth, profitability, and financial stability.

Catalysts

About Ultragenyx Pharmaceutical

A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

The accelerating global identification and diagnosis of rare diseases, supported by advancements in genomics and genetic testing, are expanding the addressable patient pool for Ultragenyx's existing and future therapies, which should drive sustained long-term revenue growth.
Healthcare payers and regulatory agencies are increasingly recognizing the value of orphan drugs, as evidenced by faster development timelines (FDA Breakthrough Therapy designation for GTX-102) and ongoing pricing/reimbursement wins in regions like Latin America and EMEA, supporting robust revenue streams and pricing power over the next several years.
Ultragenyx's clinical pipeline is advancing with five Phase III programs (including UX143 and GTX-102), multiple BLA submissions expected in the coming quarters, and near-term Phase III data readouts (notably for UX143 in OI by year-end and GTX-102 in Angelman syndrome in 2026) serving as upcoming value inflection points that can diversify and significantly accelerate the company's revenue base.
Commercial execution remains strong, with ongoing double-digit top-line growth (20% YoY revenue increase in 1H25) across a diversified, globally expanding portfolio, while new product launches (Evkeeza, continued Crysvita growth, and Dojolvi expansion) and new payer agreements in large international markets are expected to further scale revenues and improve operating leverage.
Ongoing investment and leadership in gene therapy and mRNA modalities positions Ultragenyx to benefit from process technology improvements that enable scalable, lower-cost manufacturing of complex biologics, offering the prospect of higher long-term margins and improving the company's path to profitability (targeted for GAAP break-even in 2027).

Ultragenyx Pharmaceutical Earnings and Revenue Growth

Ultragenyx Pharmaceutical Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Ultragenyx Pharmaceutical's revenue will grow by 25.4% annually over the next 3 years.
Analysts assume that profit margins will increase from -90.9% today to 8.6% in 3 years time.
Analysts expect earnings to reach $114.0 million (and earnings per share of $0.98) by about June 2029, up from -$609.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $321.3 million in earnings, and the most bearish expecting $-177.9 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 60.0x on those 2029 earnings, up from -3.8x today. This future PE is greater than the current PE for the US Biotechs industry at 16.4x.
Analysts expect the number of shares outstanding to grow by 2.07% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent lack of profitability and a high cash burn rate-Ultragenyx reported a net loss of $115 million in Q2 2025 and expects net cash used in operations to increase in 2025, risking dilution or financial strain if revenue ramp-up and cost control do not materialize, which would negatively impact future earnings and margins.
Heavy reliance on regulatory success for pipeline assets (e.g., UX111 and DTX401)-recent delays due to a Complete Response Letter (CRL) from the FDA and CMC issues highlight vulnerability to further regulatory or operational setbacks, which could result in unpredictable or declining revenue streams.
Increasing pricing and reimbursement pressure-commercial performance relies on navigating country-by-country pricing negotiations and payer approval, with acknowledgments of "lumpiness" and risk of future tighter restrictions from governments or payors, potentially constraining long-term topline revenue growth.
Intensifying industry competition and technological disruption-rising competition in the rare disease and gene therapy space (including gene-editing and CRISPR technologies) alongside the risk that new modalities could outpace existing Ultragenyx treatments, posing threats to revenue sustainability and gross margin stability.
Dependence on Priority Review Vouchers (PRVs) and successful launches for achieving future profitability-company guidance assumes receipt and monetization of multiple PRVs, but timing and regulatory reauthorization risks around the PRV program or launch execution shortfalls could delay or reduce anticipated cash inflows, impacting liquidity and earnings targets.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $52.05 for Ultragenyx Pharmaceutical based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $96.0, and the most bearish reporting a price target of just $25.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.3 billion, earnings will come to $114.0 million, and it would be trading on a PE ratio of 60.0x, assuming you use a discount rate of 8.0%.
Given the current share price of $23.31, the analyst price target of $52.05 is 55.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ultragenyx Pharmaceutical?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Advancements In Genomics And Rare Therapies Will Expand Prospects